Intravenous Iron Drugs Market to Grow at a Brisk Rate During Forecast Period
Increasing cases of renal disease and growing requirement of
dialysis to drive global intravenous iron drugs through 2025
According to TechSci Research report, “Global Intravenous Iron Drugs Market By Application
(Intestinal malabsorption syndromes, Inflammatory diseases,
Gastrectomy/bariatric surgery, Anemia, Osier-Weber-Rendu disease,
Angiodysplasia, Pregnancy, Others), By Product (Iron dextran, Ferric gluconate,
Iron sucrose, Ferric carboxymaltos, Iron isomaltoside 1000, Ferumoxytol), By
End-User (Hospitals, Clinics, Others), By Region, Forecast & Opportunities,
2025”, global market
for intravenous iron drugs is expected to grow at a brisk rate throughout the
forecast period. Iron is a major element in the composition of hemoglobin and
helps in the transportation of oxygen in the entire body. Intravenous iron
drugs are infused externally within the body with the help of needles to the
patients who are unable to consume iron via oral drugs. These drugs are
prescribed by doctors to anemic people or the ones who are deficient of iron.
As per the survey conducted in 2017 by Vitamin and Mineral Nutrition
Information System, 30% of anemia in children and women in developing countries
is because of the deficiency of iron. Increasing anemic cases coupled with
increasing patient pool undergoing dialysis are driving the growth of the
market. Surging investments by governments and leading companies in the production
and research on intravenous iron drugs is propelling the growth of the market.
Anemia is also prevalent in pregnant women which can
be harmful for mothers as well as their unborn babies. Thus, intravenous iron
drugs are indispensable to both, pregnant mothers and their babies. This is
also one of the key factors leading to the growth of the market. There has been
an evident rise in the awareness of people about chronic diseases such as
anemia, bowel disease, etc., due to which they opt for intravenous iron drugs,
thereby fueling the market growth. However, these drugs have some side effects
which might impede the growth of the market.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Global
Intravenous Iron Drugs Market"
https://www.techsciresearch.com/report/intravenous-iron-drugs-market/5093.html
Global intravenous iron drugs market is segmented
based on application, product, end-user, company and region. Based on product,
the market is segregated into iron dextran, ferric
gluconate, iron sucrose, ferric carboxymaltose, iron isomaltoside 1000 and ferumoxytol.
Ferric carboxymaltose segment held the largest share in the market in the year
2019 because of its wide range of applications in the field of drug discovery.
This FDA approved drug exhibits superior performance and is available at
reduced costs. The end-user segment is divided into hospitals, clinics and
others, out of which, clinics are expected to hold the largest share until 2025
as due to surge in the use of intravenous drugs at clinics. There are a lot of
people undergoing dialysis lately, and clinics provide a platform for this
purpose. They even administer iron dosages and ensure safe and reliable
intravenous drug transmission.
Download Sample
Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5093
Customers can also request for 10% free
customization on this report.
Some of the leading players in global intravenous
iron drugs market include AMAG pharmaceuticals, Inc., Vifor Pharma Group,
Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan
PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda
Pharmaceutical Company Limited, Bausch Health Companies Inc., Shield
Therapeutics PLC, Merck & Co., Inc. and Biocon Limited.
“North America held the dominant position in
2019 in the global intravenous iron drugs market due to rising patient pool of
anemia and various other diseases such as bowel disease. In addition to this,
easy access to these drugs and advanced healthcare infrastructure is working in
the favor of the market growth in the region. However, market in the
Asia-Pacific region is expected to witness the maximum expansion during the forecast
period as population in the emerging economies such as India and China is
gradually becoming aware of the benefits of intravenous iron drugs.,” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Global
Intravenous Iron Drugs Market By Application (Intestinal malabsorption
syndromes, Inflammatory diseases, Gastrectomy/bariatric surgery, Anemia,
Osier-Weber-Rendu disease, Angiodysplasia, Pregnancy, Others), By Product (Iron
dextran, Ferric gluconate, Iron sucrose, Ferric carboxymaltos, Iron
isomaltoside 1000, Ferumoxytol), By End-User (Hospitals, Clinics, Others), By
Region, Forecast & Opportunities, 2025”, has evaluated the future growth
potential of global Intravenous iron drugs market and provided statistics &
information on market size, shares, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges and
opportunities in global intravenous iron drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]